Japan’s Morimatsu Group completed its acquisition of Bioengineering AG. The move positions Bioengineering to broaden its market presence, speed up innovation and research efforts, and expand its headquarters in Wald, Zurich, which will continue to operate as Morimatsu’s Swiss hub in Europe. With more than five decades of experience, the company remains committed to supporting global clients.

Based in Wald, Zurich, Bioengineering specializes in tailored bioprocess control systems, engineering solutions, and plant construction for the pharmaceutical and biotechnology industries worldwide. Morimatsu, employing roughly 5,000 people, serves a wide range of sectors—including pharmaceuticals, CDMOs, FMCG, energy, and specialized manufacturing—by providing modular facilities, precision equipment, and integrated services.

The partnership strengthens Morimatsu’s position in the field of bioreactors and fermentation technologies while expanding its European operations through two established brands. Clients benefit from a more comprehensive solutions portfolio, the option to procure larger systems from a reliable partner, and enhanced local support and responsiveness. Together, the companies aim to drive innovation, reinforce their industry leadership, and create a more resilient global platform.

TCFG (IMAP Switzerland) served as the sellers’ lead advisor in the transaction.